in-vitro-tumor-cell-rechallenge-for-predictive-evaluation-chimeric

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

The field of chimeric antigen receptor (CAR) T cell therapy is rapidly advancing with improvements in CAR design, gene-engineering approaches and ...

City of Hope Beckman Research Institute and Medical Center

T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen receptor (CAR) T cell immunotherapy targeting IL-13 receptor α2 (IL13Rα2) for the treatment of GBM. Here, we describe the optimization of IL13Rα2-targeted CAR T cells, including the design of a 4-1BB (CD137) co-stimulatory CAR (IL13BBζ) and a manufacturing platform using enriched central memory T cells. Utilizing orthotopic human GBM models with patient-derived tumor sphere lines in NSG mice, we found that IL13BBζ-CAR T cells improved anti-tumor activity and T cell persistence as compared to first-generation IL13ζ-CAR CD8 T cells that had shown evidence for bioactivity in patients. Investigating the impact of corticosteroids, given their frequent use in the clinical management of GBM, we demonstrate that low-dose dexamethasone does not diminish CAR T cell anti-tumor activity in vivo. Furthermore, we found that local intracranial delivery of CAR T cells elicits superior anti-tumor efficacy as compared to intravenous administration, with intraventricular infusions exhibiting possible benefit over intracranial tumor infusions in a multifocal disease model. Overall, these findings help define parameters for the clinical translation of CAR T cell therapy for the treatment of brain tumors.

Xin Yang

Department of Hematology & Hematopoietic Cell Transplantation,
T Cell Therapeutics Research Laboratory,
Department of Hematology & Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory

City of Hope Beckman Research Institute and Medical Center

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Xin Yang

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Hematology & Hematopoietic Cell Transplantation,T Cell Therapeutics Research Laboratory,Department of Hematology & Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory

City of Hope Beckman Research Institute and Medical Center

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Department of Hematology & Hematopoietic Cell Transplantation,
T Cell Therapeutics Research Laboratory,
Department of Hematology & Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory